Corporate Banner
Satellite Banner
Technology
Networks
Scientific Communities
 
Become a Member | Sign in
Home>News>This Article
  News
Return

NSF Funds Research Partnership Between Bioo Scientific and Mirna Therapeutics

Published: Thursday, July 22, 2010
Last Updated: Thursday, July 22, 2010
Bookmark and Share
The funding will support tumor regression and pharmacokinetic studies on targeted delivery of microRNAs.

Bioo Scientific Corporation announced today that it has been awarded an additional $100,000 for its Small Business Innovation Research (SBIR) Phase II grant from the National Science Foundation.

The funding will support tumor regression and pharmacokinetic studies featuring escalating doses of a microRNA-based therapeutic candidate from Mirna Therapeutics, Inc., used in combination with Bioo Scientific’s targeted transport technology. The supplemental funding brings the total financial support for this phase of the NSF project to $600,000.

The targeted transport technology (T3) combines a positively charged carrier compound and an antibody that is specific to a cell surface receptor to directly deliver RNA-interfering (RNAi) mediator payloads to specific cells in the body. The carrier-antibody conjugate, loaded with an RNAi mediator, can be administered systemically or locally to an animal (or cultured cells) where it is internalized by cells bearing surface receptors that are targeted by the antibody. Upon cell entry, the RNAi mediator is released from the T3 delivery vehicle and allowed to silence the expression of its intended targets. Bioo Scientific has been expanding its collection of antibody carrier controls and recently launched a conjugation kit to enable customers to develop antibody delivery vehicles in their own laboratories.

The RNAi mediator provided by Mirna Therapeutics is a mimic of the potent tumor suppressor microRNA, miR-34, which has proven to be effective and safe when used in animal models of cancer. miR-34 is a key component of the p53 tumor suppressor pathway and is responsible for regulating multiple cancer-related genes and cellular processes.


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,100+ scientific posters on ePosters
  • More Than 4,500+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Bioo Scientific Awarded $550K to Improve Single Cell Sequencing Technologies
The first grant, Sequencing of Epigenetic Modifications from Single Cells, will be used to further the development of single-cell methylome sequencing for use in a number of applications.
Monday, April 11, 2016
Bioo Scientific Granted Patent
Company has announced that the USPTO has issued U.S. patent for improving data quality and small RNA sequencing technology.
Wednesday, March 16, 2016
The MaxSignal Colistin ELISA Test Kit from Bioo Scientific
Kit can help prevent the antibiotic apocalypse by keeping last resort drugs out of the food supply.
Thursday, November 26, 2015
Bioo Scientific Receives USDA Approval
Approval for using its ELISA to screen meat for ractopamine residues.
Thursday, September 03, 2015
Bioo Scientific Partners with the Icahn School of Medicine at Mount Sinai
Partnership to reduce ligation bias in next generation sequencing.
Saturday, February 14, 2015
Bioo Scientific and Icahn School of Medicine Partner
Bioo Scientific partners with the Icahn School of Medicine at Mount Sinai to reduce ligation bias in next generation sequencing.
Tuesday, February 10, 2015
Bioo Scientific Awarded $750,000 NSF Grant
Company awarded a National Science Foundation Phase II grant to continue development efforts to improve the accuracy of small RNA expression analysis.
Wednesday, November 26, 2014
Bioo Scientific Receives Presidential Award for Exports
Awards are the highest recognition any U.S. entity may receive for making a significant contribution to the expansion of U.S. exports.
Thursday, May 29, 2014
Bioo Scientific Awarded Funding from NSF for the Biomolecular Detection of miRNA
The funding allows Bioo Scientific to develop a quantitative technology to measure miRNA expression in living cells or tumor tissue.
Wednesday, December 08, 2010
Bioo Scientific Awarded Funding from NSF for the Biomolecular Detection of miRNA
Bioo Scientific announced today that it has been awarded a grant of $150,000 from the National Science Foundation to support its research for the biomolecular detection of microRNA.
Wednesday, December 08, 2010
Bioo Scientific Chooses Eureka Genomics as its Next-Generation Sequencing Provider
Bioo Scientific chose Eureka Genomics based on their extensive sequencing experience, quick turnaround times and strong bioinformatics support.
Thursday, August 19, 2010
Small RNA Barcoding for Sample Multiplexing
AIR Barcoded Adapters, designed to work with Illumina Next-Generation Sequencers, provide flexibility in high-throughput sequencing applications.
Monday, January 25, 2010
Bioo Scientific and Texas Tech Collaborate to Suppress the Progression of HIV Using Targeted RNAi
Dr Premlata Shankar, Professor and Co-Director, Center of Excellence of Infectious Disease Research at Texas Tech University, who has developed RNAi-based treatment methods for HIV infection, recently entered into a collaborative research agreement with Bioo Therapeutics, a division of Bioo Scientific, to leverage their T3™ technology to facilitate the targeted delivery of siRNA into T cells.
Tuesday, November 17, 2009
Bioo Scientific Launches a New Division, Bioo Therapeutics
Bioo Therapeutics will leverage Bioo Scientific’s proprietary drug delivery vehicles and antibody research expertise to develop therapeutic agents.
Thursday, November 12, 2009
Bioo Scientific Awarded SBIR Grant for Development of Targeted RNAi In Vivo Delivery Technology
A $500,000 Phase II grant will help to develop kits and reagents based on the patent-pending Targeted Transport Technology.
Wednesday, July 29, 2009
Scientific News
The Rise of 3D Cell Culture and in vitro Model Systems for Drug Discovery and Toxicology
An overview of the current technology and the challenges and benefits over 2D cell culture models plus some of the latest advances relating to human health research.
Grant Supports Project To Develop Simple Test To Screen For Cervical Cancer
UCLA Engineering announces funding from Bill and Melinda Gates Foundation.
Injecting New Life into Old Antibiotics
A new fully synthetic way to make a class of antibiotics called macrolides from simple building blocks is set to open up a new front in the fight against antimicrobial drug resistance.
Insight into Bacterial Resilience and Antibiotic Targets
Variant of CRISPR technology paired with computerized imaging reveals essential gene networks in bacteria.
Advancing Protein Visualization
Cryo-EM methods can determine structures of small proteins bound to potential drug candidates.
Alzheimer’s Protein Serves as Natural Antibiotic
Alzheimer's-associated amyloid plaques may be part of natural process to trap microbes, findings suggest new therapeutic strategies.
Slime Mold Reveals Clues to Immune Cells’ Directional Abilities
Study from UC San Diego identifies a protein involved in the directional ability of a slime mold.
How Do You Kill A Malaria Parasite?
Drexel University scientists have discovered an unusual mechanism for how two new antimalarial drugs operate: They give the parasite’s skin a boost in cholesterol, making it unable to traverse the narrow labyrinths of the human bloodstream. The drugs also seem to trick the parasite into reproducing prematurely.
Illuminating Hidden Gene Regulators
New super-resolution technique visualizes important role of short-lived enzyme clusters.
Supressing Intenstinal Analphylaxis in Peanut Allergy
Study from National Jewish Health shows that blockade of histamine receptors suppresses intestinal anaphylaxis in peanut allergy.
Scroll Up
Scroll Down
Skyscraper Banner

Skyscraper Banner
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,100+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,500+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!